{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-25-021008","form_type":"8-K","ticker":"LPCN","cik":"0001535955","company_name":"Lipocine Inc.","filed_at":"2025-11-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.680699+00:00","generated_at":"2026-05-16T23:40:30.869557+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Lipocine Q3 net loss widens to $3.2M; cash drops to $15.1M; PPD trial on track","bullets":["Net loss of $3.2M ($0.59/sh) vs $2.2M loss ($0.44/sh) in Q3 2024.","Cash & investments $15.1M at Sep 30, 2025, down from $21.6M at Dec 31, 2024.","R&D spend $2.7M (+69% YoY) driven by LPCN 1154 Phase 3 PPD trial; top-line data expected Q2 2026.","TLANDO royalty revenue $115k; nine-month license revenue $500k vs $7.5M prior year from Verity deal.","LPCN 2101 abstracts accepted for AES meeting Dec 5-9; exploring partnerships for multiple assets."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-25-021008","json":"https://secwatch.observer/filing/0001493152-25-021008.json","markdown":"https://secwatch.observer/filing/0001493152-25-021008.md","text":"https://secwatch.observer/filing/0001493152-25-021008.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1535955/000149315225021008/0001493152-25-021008-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1535955/000149315225021008/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T23:40:30.869557+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}